Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Taste Physiology in Healthy, Normal-weight Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02255812
Recruitment Status : Completed
First Posted : October 3, 2014
Last Update Posted : October 3, 2014
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
Taste physiology describes five main taste qualities in humans: sweet, sour, salty, umami and bitter. The receptors found on the tongue are also found in the entire gut. The correlation of stimulation of these gut receptors and brain activity has not yet been examined. The objectives are to investigate the effect of different taste substances on i) regional brain activity and ii) satiation peptide release.

Condition or disease Intervention/treatment Phase
Exploratory Behavior Dietary Supplement: Single intragastric instillation of 200 mL tap water via nasogastric tube Dietary Supplement: Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube Dietary Supplement: Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube Dietary Supplement: Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube Dietary Supplement: Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube Dietary Supplement: Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Taste Physiology in Healthy, Normal-weight Volunteers
Study Start Date : March 2013
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: 200 mL tap water
Single intragastric instillation of 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 200 mL tap water via nasogastric tube
Active Comparator: 2 g citric acid
Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
Active Comparator: 2 g salt
Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
Active Comparator: 0.017 g quinine
Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
Active Comparator: 1 g monosodium glutamate
Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
Active Comparator: 25 g glucose
Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
Dietary Supplement: Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube



Primary Outcome Measures :
  1. regional brain activity assessed by functional Magnetic Resonance Imaging (fMRI) [ Time Frame: changes from baseline to one hour after treatment ]
    Changes in resting state functional connectivity


Secondary Outcome Measures :
  1. gastrointestinal satiation peptide secretion [ Time Frame: changes from baseline to one hour after treatment ]
    Unit of Measure: glucagon like peptide-1 (GLP-1) in pg/mL, peptide tyrosine tyrosine (PYY) in pg/mL and gastric inhibitory polypeptide (GIP) in pg/mL

  2. glucose and insulin secretion [ Time Frame: changes from baseline to one hour after treatment ]
    Unit of Measure: glucose in mmol/L, insulin in μU/mL



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • right-handed healthy males
  • Body-mass index of < 25
  • Age 18-45 years
  • no drugs
  • non-smoking

Exclusion Criteria:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness, especially: diabetes, pace-maker, claustrophobia
  • History of gastrointestinal disorders
  • Food allergies, glutamate intolerance
  • Body piercings that cannot be removed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255812


Locations
Layout table for location information
Switzerland
University Hospital
Basel, Switzerland, CH-4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Christoph Beglinger, MD University Hospital, Basel, Switzerland
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT02255812    
Other Study ID Numbers: EKBB 289/12/2
First Posted: October 3, 2014    Key Record Dates
Last Update Posted: October 3, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Quinine
Citric Acid
Sodium Citrate
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action